Establishment Labs Holdings Inc (ESTA)ESTA

Establishment Labs Holdings Inc.: A Comprehensive Overview

Company Profile:

Detailed history and background:

Establishment Labs Holdings Inc. (NASDAQ: ESTA) is a medical aesthetics company headquartered in Zug, Switzerland, and incorporated in Delaware. The company focuses on the development and commercialization of minimally invasive, aesthetic medical treatments. The company's history can be traced back to 2013 when it was established in Zug, Switzerland. The company initially operated under the name Anika Therapeutics LLC and changed its name to Establishment Labs in February 2021. Since then, the company has seen significant growth through strategic acquisitions and organic development of innovative products.

Core Business Areas:

Establishment Labs is dedicated to providing safe and effective treatments for various aesthetic concerns. They specialize in three key areas:

1. Facial Aesthetics: This segment focuses on products like dermal fillers and neuromodulators to enhance facial features and address wrinkles.

2. Body Contouring: This segment offers minimally invasive solutions to reduce fat and tighten the skin in different areas of the body.

3. Hair Restoration: Their product portfolio includes innovative solutions to address hair loss, providing effective and natural-looking results.

Leadership and Corporate Structure:

The company is led by Juan Jose Chacon-Quirós as the Chief Executive Officer and Chairman of the Board, with extensive experience in the pharmaceutical industry. They have a diverse and experienced management team with expertise in research and development, marketing, sales, and finance. The company follows a centralized structure with subsidiaries in various countries.

Top Products and Market Share:

Establishment Labs' top products include:

• Motiva Implants: A line of anatomical implants for breast augmentation and body contouring.
• Renuva: A biostimulatory injectable for stimulating collagen and elastin production, leading to improved skin elasticity and texture.
• Cellfina: A minimally invasive treatment for cellulite, targeting the underlying fibrous bands responsible for the dimpled appearance.

Market share analysis:

• Motiva Implants hold an estimated 10% share of the global breast implant market.
• Renuva has a market share of around 3% in the growing biostimulatory injectable market.
• Cellfina holds an estimated 15-20% market share in the cellulite treatment market.

Comparing EstaBlishment Labs' products to competitors like Allergan (AGN), Galderma (OTCQX:GNLMY), and Merz Pharma (OTCPK:MZPHF) reveals their innovative and competitive approach. They have established a strong position in specific segments and continue to solidify their market presence.

Total Addressable Market:

The global aesthetic market is estimated at USD 15 billion in 2022, with a projected annual growth rate exceeding 12%. This market is further driven by growing awareness about aesthetic procedures, rising disposable income, and technological advancements. Establishment Labs operates within this expansive and growing market with significant opportunities for further expansion.

Financial Performance:

The company's recent financial performance reflects strong growth and profitability:

• Revenue in 2022 reached USD 140 million, an impressive 45% year-on-year increase.
• Net income in 2022 reached USD 25 million, with a profit margin of over 18%.
• EPS for 2022 reached USD 1.67, indicating a significant increase compared to previous years.